Driving forward Phase 3 DIAMOND trials of OCS-01 eye drops, a topical OPTIREACH formulation of high-concentration dexamethasone for DME
Time: 10:00 am
day: Day Two
Details:
- Highlighting the OPTIREACH formulation technology and associated benefits
- Discussing remaining unmet medical needs for DME patient management
- Exploring the clinical evidence to date on the efficacy and safety of OCS-01 eye drops for DME
